Alpine Immune Sciences, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 17.92 million compared to USD 13.27 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.28 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.97 USD | +0.02% | -.--% | +240.87% |
1st Jan change | Capi. | |
---|---|---|
+240.87% | 4.46B | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+2.18% | 22.67B | |
-10.09% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- ALPN Stock
- News Alpine Immune Sciences, Inc.
- Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024